Broken String Biosciences launched BaseMap ABE, a platform meant to standardize genome-wide off-target characterization for adenine base editing (ABE) therapeutic development. The company said the approach generates data directly in biologically relevant cells, aiming to reduce reliance on prediction-only methods. The release positions BaseMap ABE as an early step in a broader product expansion into base editing applications, with an Early Access Program offered to researchers building genome editing therapies. The company emphasized reproducibility and standardized reporting of unintended editing events to support guide optimization, editor selection, and preclinical decision-making. For the gene editing market, the move is notable because ABE programs increasingly need consistent evidence of editing specificity to de-risk translation across guide designs and cellular contexts—an area where variability has complicated comparisons between programs.